TSI Investor Profile: Inmed
Featured Video
Company Brief
Proprietary Drug/Disease Targeting Tool
InMed’s proprietary bioinformatics algorithm assesses the different active sites on cannabinoids and screens them against approved drug structures, disease site receptors, genetic profiles of diseases, and the involvement of proteins and chemical metabolites in disease pathways. This program then selects specific cannabinoids (or combinations thereof) that might play a role in regulating diseases.
Summary
Fiscal Year-End: December
License Renewal Month: October 2017
Licenses: 1
Licensed Capacity: N/A
Number of Patients: N/A
Headquarters: Vancouver, BC
Financials (pro forma 09/30)
Cash on hand: $2.7mm
Fixed Investment: $5.72mm
Shareholders’ Equity: $17.8mm
Revenues – Last Quarter: N/A
Adj. Gross Margin: N/A
EPS: N/A
Capital Structure (07/31/17)
Last Financing: xx mm shares at $0.xx
Basic Shares: 97.20mm
Warrants: 14.1mm
Options: 14.7mm
Diluted Shares: 121.9mm
Highlights
- Broad portfolio of assets in dermatology, ocular diseases, additional indications and cannabinoid biosynthesis
- Positioning to achieve value-driving, near-term milestones with limited investment:
- Experienced team capable of building value in biopharmaceuticals
Growth Strategy
- Lead drug candidate in an orphan paediatric disease with high unmet medical need; final formulation development, toxicology and Ph1-2a clinical trials targeted for completion within 24 months from financing
- Biosynthesis of cannabinoids aimed to be commercial ready within 24 months from financing
- Active discussions to license production to U.S. operators
Differentiators
- Bioinformatics Database Proprietary computer-based drug/disease target screening tool
- Biosynthesis Proprietary cannabinoid manufacturing system
- Drug Development Pipeline Expedited drug development timelines, conservative clinical budget targeting high unmet medical conditions utilizing disease-specific formulations:
- INM-750 for Epidermolysis Bullosa – An orphan paediatric disease characterized by extremely fragile skin with no current approved therapies. Potential global market revenues of ~US$1B.
- INM-085 for Glaucoma – A serious eye disease with a global market of >US$5B
Drug Development
R&D Timelines
Strong Management Team
Eric A. Adams CEO + President - 25+ years’ experience in global biopharmaceutical business development, Sales, Marketing, M&A with enGene, QLT, Advanced Tissue Sciences, Abbott Laboratories, Fresenius AG
Dr. Sazzad Hossain Chief Scientific Officer, PhD, M.Sc. - 20+ years of academic/industry experience in drug discovery and product development at Xenon Pharmaceuticals, targeting pain, inflammation and cardiovascular diseases; and Canada’s National Research Council
Dr. Ado Muhammad Chief Medical Officer, MD, DPM, MFPM - Former Associate Medical Director at GW Pharmaceuticals specializing in the development of cannabinoid-based prescription medicines
Jeff Charpentier Chief Financial Officer + Corporate Secretary - 25+ years’ experience in biotech and technology companies including Lifebank Corp., Inex Pharmaceuticals, and Chromos Molecular Systems Inc.
Alexandra Mancini Sr. Vice President, Clinical and Regulatory Affairs, M.Sc. - 30 years’ global biopharmaceutical R&D experience with Sirius Genomics, Inex Pharmaceuticals, and QLT Inc.
Related Articles
Horizons ETFs Expands the Portfolio of its Marijuana-Focused ETF, Adding InMed
InMed's addition to Canada’s Cannabis ETF Could Be Signalling the Start of a Big New Investing Theme = Biotechs.
Advanced Biosynthesis Setting New Standards for Cannabinoid-based Pain Management
One pioneering biopharmaceutical company, InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), has triggered a paradigm shift in discovering potential breakthrough cannabinoid-based therapies. .-
Purified Cannabinoids Open New Opportunities in Pain Management
As consumer acceptance continues to propel demand to unprecedented levels, companies such as InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) are making waves in the advancement of cannabinoid compounds as a medical solution in pain management and other indications.-
ABcann Global Adds Big Alcohol, Big Tobacco and Big Pharma Experience to the Team
Mr. Rick Fitzgerald brings extensive strategic marketing and senior leadership in the alcoholic beverage and tobacco industries to the Board of Directors. Dr. Michael Bumby brings extensive financial, international and capital markets experience to the executive team as Chief Financial Officer
InMed to Present at Cannabis-Based Science & Medicine Conference
InMed will present at the Biopharma Forum on 'Cannabis-Based Science & Medicine' conference on Thursday, November 30th and Friday, December 1st, 2017 in Denver, CO.
INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) Is Running: Here’s Why
Insider Financial looks at the recent market run by InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF)
Biosynthesis: Making the Impossible Possible in Medicinal Cannabis
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) breakthrough biosynthesis process allows it to control the entire drug development process, in house – and without the inherent challenges of traditional agricultural cultivation methods.
Biotech Pushes Forward Disease Treatment Potential of Non-Psychoactive Cannabinoids - From Cashinbis
Cashinbis looks at InMed's exciting cannabis biotech research and what it could mean for the treatment of multiple diseases in an interview with CEO Eric Adams.
InMed (CSE: IN; OTCQB: IMLFF) Uses Expertise to Create Shareholder Value
Looking at how the expertise of InMed's management, consulting and advisory team combines to drive value for shareholders.
Is InMed Pharmaceuticals (OTCQB:IMLFF) The Next Big Thing In Cannabis?
Financials Trend thinks that InMed is a "four-bagger" of an investment thanks to proven expertise, a proprietary cutting-edge technology and TWO drugs already heading towards clinical trials that could quickly position InMed as a major player.
INMED PHARMACEUTICALS (CSE: IN; OTCMKTS: IMLFF) Could Be Poised For Gains
InMed Pharmaceuticals is a turnaround stock, with recent news updates showing promise for future gains
Biosynthetic cannabinoids could be the way of the future
InMed Pharmaceuticals develops technology to bridge the gap between synthetic and natural cannabinoids.